MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2017 International Congress

    Epitope mapping of CSF auto-antibodies to alpha-synuclein

    R. Akhtar, J. Licata, K. Luk, D. Covell, J. Trojanowski, V. Lee (Philadelphia, PA, USA)

    Objective: To identify α-synuclein (α-syn) epitopes bound by endogenous auto-antibodies in CSF from healthy controls (HC) and Parkinson disease (PD) patients. Background: In PD, endogenous…
  • 2017 International Congress

    Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease.

    C. Friedrich, W. Zago, S. Gardai, G. Tonn, M. Reed (Cupertino, CA, USA)

    Objective: Objective: In order to improve the understanding of the alpha-synuclein system and its role in Parkinson’s disease, Elan and Rosa collaborated in the development…
  • 2017 International Congress

    AAV-mediated human alpha synuclein overexpression in the locus coeruleus (LC) leads to a neuronal loss in the nucleus ambiguus of mouse.

    B. Lee, M. Henrich, W.-H. Chiu, L. Matschke (Marburg, Germany)

    Objective: To investigate the impact and temporal aspects of the neuronal loss in the LC neurons induced by alpha-synucleinopathy Background: In the Braak staging model…
  • 2017 International Congress

    The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

    T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)

    Objective: Using preclinical models, assess the potential disease-modifying effects of nortriptyline (NOR) as a treatment in early Parkinson’s disease (PD). Background: PD and other synucleinopathies…
  • 2017 International Congress

    Alpha-synuclein protein homeostasis and oligomerization in iron-overloaded cells expressing mutant HFE

    Y. Kim, J. Connor, M. Stahl (Hershey, PA, USA)

    Objective: Study the direct and indirect effects of iron overload on alpha synuclein homeostasis in a genetic model of hemochromatosis (HFE) Background: Parkinson’s disease (PD)…
  • 2017 International Congress

    Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy

    W. Meissner, F. Bassil, P. Guerin, N. Dutheil, Q. Li, M. Klugmann, E. Bezard, P.-O. Fernagut (Bordeaux, France)

    Objective: We aimed to develop AAV-based models of MSA Background: Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by a combination of autonomic…
  • 2017 International Congress

    Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

    C. Linder, B. Mollenhauer, C. Coffey, T. Beach, T. Foroud, C. Adler, H. Riss, D. Ecklund, C. Caspell-Garcia, K. Dave, S. Deshpande, S. Lasch, V. Arnedo, L. Riley, C. Kopil, D. Jennings, L. Chahine (Philadelphia, PA, USA)

    Objective: The S4 study aims to characterize the distribution of alpha-synuclein (aSyn) pathology in multiple tissues and body fluids within the same Parkinson’s disease (PD)…
  • 2017 International Congress

    Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy

    E. Rockenstein, G. Ostroff, F. Dikengil, F. Rus, M. Mante, J. Florio, A. Adame, I. Trinh, E. Masliah, R. Rissman (La Jolla, CA, USA)

    Objective: Test the hypothesis that combining humoral and immunosuppressive cellular asyn immunization will enhance asyn clearance, and reduce inflammation and neuropathological symptoms in a human…
  • 2016 International Congress

    Hypothalamic alpha-synuclein pathology and its relation to non-motor symptoms and disease progression in Parkinson’s disease

    E. De Pablo-Fernandez, R. Courtney, J.L. Holton, T.W. Warner (London, United Kingdom)

    Objective: To assess alpha-synuclein pathology and tyrosine hydroxylase (TH) immunoreactivity as a dopaminergic marker in three hypothalamic nuclei with potential clinical implications (paraventricular, supraoptic and…
  • 2016 International Congress

    Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker

    S.J. Chung, J. Kim, H.J. Lee, H.S. Ryu, K.W. Jung, M.J. Kim, M.J. Kim, S.M. Hong, S.J. Myung (Seoul, Korea)

    Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • #25179 (not found)
  • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley